GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zymeworks Inc (FRA:ZA8) » Definitions » Debt-to-Revenue

Zymeworks (FRA:ZA8) Debt-to-Revenue : 0.63 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Zymeworks Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Zymeworks's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €3.82 Mil. Zymeworks's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €19.38 Mil. Zymeworks's annualized Revenue for the quarter that ended in Mar. 2024 was €36.91 Mil. Zymeworks's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 0.63.


Zymeworks Debt-to-Revenue Historical Data

The historical data trend for Zymeworks's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zymeworks Debt-to-Revenue Chart

Zymeworks Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.23 0.22 1.21 0.07 0.35

Zymeworks Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.19 0.97 0.40 0.40 0.63

Competitive Comparison of Zymeworks's Debt-to-Revenue

For the Biotechnology subindustry, Zymeworks's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zymeworks's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zymeworks's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Zymeworks's Debt-to-Revenue falls into.



Zymeworks Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Zymeworks's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(3.907 + 20.597) / 69.703
=0.35

Zymeworks's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(3.823 + 19.383) / 36.912
=0.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.


Zymeworks Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Zymeworks's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Zymeworks (FRA:ZA8) Business Description

Traded in Other Exchanges
Address
108 Patriot Drive, Suite A, Middletown, DE, USA, 19709
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Zymeworks (FRA:ZA8) Headlines

No Headlines